Talphera (NASDAQ:TLPH - Get Free Report) will likely be posting its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect Talphera to announce earnings of ($0.06) per share for the quarter. Investors may visit the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:30 PM ET.
Talphera (NASDAQ:TLPH - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.06) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.06). On average, analysts expect Talphera to post ($0.23) EPS for the current fiscal year and ($0.27) EPS for the next fiscal year.
Talphera Trading Up 3.8%
Shares of TLPH opened at $1.05 on Wednesday. The stock has a market capitalization of $54.40 million, a P/E ratio of -3.85 and a beta of 0.77. Talphera has a 12 month low of $0.69 and a 12 month high of $1.57. The firm's fifty day simple moving average is $1.14 and its two-hundred day simple moving average is $1.01.
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Talphera to a "hold" rating in a report on Saturday, August 8th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Talphera in a research report on Thursday, October 15th. Finally, HC Wainwright restated a "buy" rating and issued a $3.00 target price on shares of Talphera in a research report on Thursday, August 13th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Talphera has a consensus rating of "Hold" and a consensus price target of $3.00.
Check Out Our Latest Stock Report on Talphera
About Talphera
(
Get Free Report)
Talphera, formerly known as AcelRx Pharmaceuticals, is a specialty pharmaceutical company focused on developing and commercializing therapies for acute pain. The company's lead product is DSUVIA, a sublingual tablet containing sufentanil, an opioid analgesic designed to provide rapid relief for adults experiencing acute pain severe enough to require an opioid.
DSUVIA is intended for use in medically supervised settings, including hospitals, surgical centers and other certified health-care environments.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Talphera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Talphera wasn't on the list.
While Talphera currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.